CN Patent

CN101652068A — 激酶抑制物化合物

Assigned to Tyrogenex Inc · Expires 2010-02-17 · 16y expired

What this patent protects

吡啶和哒嗪衍生物作为蛋白质激酶的抑制物具有意外的药物性质，在治疗与异常蛋白激酶活性相关的失调例如癌症中是有用的。

USPTO Abstract

吡啶和哒嗪衍生物作为蛋白质激酶的抑制物具有意外的药物性质，在治疗与异常蛋白激酶活性相关的失调例如癌症中是有用的。

Drugs covered by this patent

ensartinib-hydrochloride (ENSARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN101652068A
Jurisdiction: CN
Classification: —
Expires: 2010-02-17
Drug substance claim: No
Drug product claim: No
Assignee: Tyrogenex Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.